http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110407934-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-765 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate | 2019-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110407934-B |
| titleOfInvention | Anti-human albumin mixed antibody and determination kit |
| abstract | The invention provides an anti-human albumin mixed antibody and a determination kit. The mixed antibody comprises an anti-human albumin antibody 1 (an anti-human ALB antibody 1) and an anti-human albumin antibody 2 (an anti-human ALB antibody 2), wherein the lower linear limit of the anti-human ALB antibody 1 on the mALB detection is 5-30 mg/L, and the upper linear limit of the anti-human ALB antibody 2 on the mALB detection is 1800-2000 mg/L. The mixed antibody can give consideration to the advantages of high sensitivity and high detection range, and simultaneously achieves the unexpected synergistic effect exceeding the characteristics of the two antibodies, so that the screening of normal people in clinical application (5mg/L can be detected at the lowest value) can be met, the dilution work of higher-concentration samples (1875-2500 mg/L) is reduced, and the missed diagnosis of high-concentration patients (HOOK effect does not occur under high concentration) can be avoided. |
| priorityDate | 2019-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.